460 related articles for article (PubMed ID: 34782755)
1. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
[TBL] [Abstract][Full Text] [Related]
3. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Ricardo-Silgado ML; Singh S; Cifuentes L; Decker PA; Gonzalez-Izundegui D; Moyer AM; Hurtado MD; Camilleri M; Bielinski SJ; Acosta A
BMC Med; 2022 Jul; 20(1):261. PubMed ID: 35879764
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
[TBL] [Abstract][Full Text] [Related]
5. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
[TBL] [Abstract][Full Text] [Related]
6. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GAPJM; Weide JV; Wilffert B; Swen JJ; Guchelaar HJ; Deneer VHM; van Schaik RHN
Eur J Hum Genet; 2022 Oct; 30(10):1105-1113. PubMed ID: 34267337
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy.
Hippman C; Slomp C; Morris E; Batallones R; Inglis A; Carrion P; Brain U; Higginson M; Wright GEB; Balneaves LG; Ryan D; Nislow C; Ross CJD; Gaedigk A; Oberlander TF; Austin J
Arch Womens Ment Health; 2022 Apr; 25(2):355-365. PubMed ID: 34231053
[TBL] [Abstract][Full Text] [Related]
9. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes.
Berle JØ; Steen VM; Aamo TO; Breilid H; Zahlsen K; Spigset O
J Clin Psychiatry; 2004 Sep; 65(9):1228-34. PubMed ID: 15367050
[TBL] [Abstract][Full Text] [Related]
10. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
[TBL] [Abstract][Full Text] [Related]
11. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
Chang M; Tybring G; Dahl ML; Lindh JD
Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.
Rossow KM; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 33234666
[TBL] [Abstract][Full Text] [Related]
13. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
14. Influence of
Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.
Honeycutt DC; Blom TJ; Ramsey LB; Strawn JR; Bruns KM; Welge JA; Patino LR; Singh MK; DelBello MP
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):42-51. PubMed ID: 38377518
[No Abstract] [Full Text] [Related]
16. Genotyping of patients treated with selective serotonin reuptake inhibitors.
Solhaug V; Haslemo T; Kringen MK; Molden E; Dietrichs ES
Tidsskr Nor Laegeforen; 2022 Sep; 142(13):. PubMed ID: 36164782
[TBL] [Abstract][Full Text] [Related]
17. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
18. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.
Beunk L; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Houwink EJF; Risselada A; Rongen GAPJM; van Schaik RHN; Swen JJ; Touw D; van Westrhenen R; Deneer VHM; van der Weide J
Eur J Hum Genet; 2024 Mar; 32(3):278-285. PubMed ID: 37002327
[TBL] [Abstract][Full Text] [Related]
19. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate.
Nijenhuis M; Soree B; Jama WOM; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Houwink EJF; Rongen GA; van Schaik RHN; Swen JJ; Touw D; van der Weide J; van Westrhenen R; Deneer VHM; Risselada A
Eur J Hum Genet; 2023 Dec; 31(12):1364-1370. PubMed ID: 36509836
[TBL] [Abstract][Full Text] [Related]
20. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]